KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Non-Current Assets (2016 - 2025)

Teladoc Health (TDOC) has disclosed Non-Current Assets for 12 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 6.12% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 billion through Dec 2025, down 16.26% year-over-year, with the annual reading at $1.7 billion for FY2025, 6.12% down from the prior year.
  • Non-Current Assets hit $1.7 billion in Q4 2025 for Teladoc Health, down from $1.8 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $16.6 billion in Q1 2021 to a low of $27.2 million in Q4 2021.
  • Historically, Non-Current Assets has averaged $4.9 billion across 5 years, with a median of $2.4 billion in 2024.
  • Biggest YoY gain for Non-Current Assets was 1030853.94% in 2021; the steepest drop was 99.84% in 2021.
  • Year by year, Non-Current Assets stood at $27.2 million in 2021, then increased by 8.84% to $29.6 million in 2022, then skyrocketed by 9694.95% to $2.9 billion in 2023, then crashed by 36.19% to $1.9 billion in 2024, then decreased by 6.12% to $1.7 billion in 2025.
  • Business Quant data shows Non-Current Assets for TDOC at $1.7 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.8 billion in Q2 2025.